Endocannabinoid metabolism and Alzheimer’s disease

作     者：Chu Chen Chu Chen

作者机构：Department of Cellular and Integrative PhysiologySchool of MedicineUniversity of Texas Health Science Center at San AntonioSan AntonioTXUSA 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2022年第17卷第9期

页      面：1987-1988页

核心收录：

学科分类：1002[医学-临床医学] 100203[医学-老年医学] 10[医学] 

基　　金：supported by National Institutes of Health grants R01NS076815 R01MH113535 and R01AG058621(to CC) 

主　　题：metabolism Alzheimer protective 

摘      要：Alzheimer’s disease(AD)is the most common cause of dementia in the ***,there are no effective therapies currently available for prevention and treatment of *** it is clear now,the etiology of AD is multifactorial and *** means that development of AD is linked to multiple mechanisms or signaling pathways and that a single-target therapy for AD is likely insufficient to achieve therapeutic ***,an ideal therapy for AD should be able to modify the disease through multiple signaling pathways.2-Arachidonoylglycerol(2-AG)is an endogenous cannabinoid(endocannabinoid)displayinganti-inflammator y a n d neuroprotective properties,while its metabolites are arachidonic acid(AA)and AA-derived prostaglandins and leukotrienes,which are proinflammatory and neurotoxic(Figure 1).